AZD-1222

COVID-19

Two-dose recombinant viral vector vaccine

Development status

  1. Emergency use/conditional marketing authorizations granted in multiple countries
  2. Phase 3 clinical trials underway in Brazil, Chile, Colombia, Japan, Mainland China (sublicensed to Shenzhen Kangtai Biological Products), Peru, Russia, South Africa and U.S.
  3. Korea Disease Control and Prevention Agency (KDCA) reviewing application for emergency use
34 active deals

Emergency use
authorizations granted in:

Drugs to Watch - AZD-1222 Placeholder
Drugs to Watch - AZD-1222

Distribution

The vaccine is well-tolerated, easily distributed, storable at refrigerator temperatures and easily administered.

There is some concern about its efficacy, which is as low as 59.5% as per protocol and as high as 90% with a prime-boost regimen that is not included in the planned protocol. Data are lacking for older patients (>55 years).

Drugs to Watch 2021

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team